Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
INR 106.0
(-2.0%)
INR 106.0
(-2.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 166.21 Million INR | -98.07% |
| 2022 | 8.62 Billion INR | -9.54% |
| 2021 | 9.53 Billion INR | -5.21% |
| 2020 | 10.05 Billion INR | -2.52% |
| 2019 | 10.31 Billion INR | -10.18% |
| 2018 | 11.48 Billion INR | 38.04% |
| 2017 | 8.31 Billion INR | -33.05% |
| 2016 | 12.42 Billion INR | -7.65% |
| 2015 | 13.45 Billion INR | -4.78% |
| 2014 | 14.12 Billion INR | 4.24% |
| 2013 | 13.55 Billion INR | 9.29% |
| 2012 | 12.4 Billion INR | 22.44% |
| 2011 | 10.12 Billion INR | 68.98% |
| 2010 | 5.99 Billion INR | 1.88% |
| 2009 | 5.88 Billion INR | 55.07% |
| 2008 | 3.79 Billion INR | 21.18% |
| 2007 | 3.13 Billion INR | 7.48% |
| 2006 | 2.91 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 166.21 Million INR | 0.0% |
| 2023 Q2 | 8.01 Billion INR | 0.0% |
| 2023 FY | 166.21 Million INR | -98.07% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 8.62 Billion INR | -9.54% |
| 2022 Q4 | 8.62 Billion INR | 0.0% |
| 2022 Q2 | 9.16 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 9.53 Billion INR | -5.21% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 9.72 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 9.53 Billion INR | 0.0% |
| 2020 Q4 | 10.05 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 10.05 Billion INR | -2.52% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 10.04 Billion INR | 0.0% |
| 2019 Q4 | 10.31 Billion INR | 0.0% |
| 2019 Q2 | 10.75 Billion INR | 0.0% |
| 2019 FY | 10.31 Billion INR | -10.18% |
| 2019 Q3 | - INR | -100.0% |
| 2018 FY | 11.48 Billion INR | 38.04% |
| 2018 Q4 | 11.48 Billion INR | 0.0% |
| 2017 FY | 8.31 Billion INR | -33.05% |
| 2016 FY | 12.42 Billion INR | -7.65% |
| 2015 FY | 13.45 Billion INR | -4.78% |
| 2014 FY | 14.12 Billion INR | 4.24% |
| 2013 FY | 13.55 Billion INR | 9.29% |
| 2012 Q4 | 12.4 Billion INR | 0.0% |
| 2012 FY | 12.4 Billion INR | 22.44% |
| 2012 Q2 | 14.73 Billion INR | 0.0% |
| 2011 FY | 10.12 Billion INR | 68.98% |
| 2010 FY | 5.99 Billion INR | 1.88% |
| 2009 FY | 5.88 Billion INR | 55.07% |
| 2008 FY | 3.79 Billion INR | 21.18% |
| 2007 FY | 3.13 Billion INR | 7.48% |
| 2006 FY | 2.91 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | 52.887% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -861.731% |
| Sigachi Industries Limited | 1.43 Billion INR | 88.381% |
| Bal Pharma Limited | 1.39 Billion INR | 88.098% |
| Medico Remedies Limited | 80.5 Million INR | -106.469% |
| Lasa Supergenerics Limited | 220.76 Million INR | 24.708% |
| Venus Remedies Limited | 413.3 Million INR | 59.783% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | 72.818% |
| Alpa Laboratories Limited | 52.46 Million INR | -216.813% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 97.385% |
| Shilpa Medicare Limited | 9.37 Billion INR | 98.227% |
| Aarti Drugs Limited | 5.64 Billion INR | 97.054% |
| Lupin Limited | 29.21 Billion INR | 99.431% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 99.75% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 97.933% |
| Windlas Biotech Limited | 36.41 Million INR | -356.512% |
| Suven Life Sciences Limited | 7.09 Million INR | -2242.06% |
| Eris Lifesciences Limited | 27.81 Billion INR | 99.402% |
| Valiant Laboratories Limited | 767.08 Million INR | 78.331% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 95.599% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 98.357% |
| Ipca Laboratories Limited | 14.38 Billion INR | 98.844% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 83.352% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 99.492% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 95.006% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | 91.977% |
| Laurus Labs Limited | 25.77 Billion INR | 99.355% |
| Piramal Pharma Limited | 47.1 Billion INR | 99.647% |
| Syncom Formulations (India) Limited | 724.86 Million INR | 77.069% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 99.587% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 96.761% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 98.65% |
| Unichem Laboratories Limited | 2.47 Billion INR | 93.285% |
| Sequent Scientific Limited | 4.87 Billion INR | 96.592% |
| Novartis India Limited | 69.7 Million INR | -138.473% |
| Wanbury Limited | 1.16 Billion INR | 85.731% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | 74.427% |
| Wockhardt Limited | 23.56 Billion INR | 99.294% |
| Themis Medicare Limited | 957.92 Million INR | 82.648% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -85.903% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 99.546% |
| Glenmark Life Sciences Limited | 171.48 Million INR | 3.07% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 99.17% |
| Divi's Laboratories Limited | 30 Million INR | -454.053% |
| NATCO Pharma Limited | 3.71 Billion INR | 95.522% |
| Gufic Biosciences Limited | 3.32 Billion INR | 95.007% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | 49.263% |
| Ind-Swift Limited | 10.13 Billion INR | 98.361% |
| Procter & Gamble Health Limited | 95.6 Million INR | -73.866% |
| FDC Limited | 205.18 Million INR | 18.992% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 91.407% |
| Granules India Limited | 13.15 Billion INR | 98.736% |
| Medicamen Biotech Limited | 308.17 Million INR | 46.064% |
| Alkem Laboratories Limited | 14.18 Billion INR | 98.828% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -261.481% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -3687.104% |
| Brooks Laboratories Limited | 56.41 Million INR | -194.61% |
| Megasoft Limited | 1.47 Billion INR | 88.696% |
| ZIM Laboratories Limited | 1.08 Billion INR | 84.726% |
| Strides Pharma Science Limited | 25.16 Billion INR | 99.34% |
| Neuland Laboratories Limited | 953.89 Million INR | 82.575% |
| Morepen Laboratories Limited | 289.99 Million INR | 42.683% |
| Hikal Limited | 8.17 Billion INR | 97.967% |
| Indoco Remedies Limited | 6.71 Billion INR | 97.526% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 94.173% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | 47.477% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 83.124% |
| Hester Biosciences Limited | 2.44 Billion INR | 93.198% |